The DARE-AF trial, recently published in Circulation, investigated whether the SGLT2 inhibitor Dapagliflozin could reduce the recurrence of atrial fibrillation (AFib) following ablation in patients without standard indications for the drug.
While observational data in patients with comorbidities like Heart Failure or Type 2 Diabetes suggested a protective effect against AFib recurrence, the DARE-AF study targeted a specific cohort: 200 patients scheduled for ablation who did not have diabetes, heart failure, or Chronic Kidney Disease (CKD).
Read more
DARE-AF Study Design and outcomes
Patients were randomized 1:1 to receive either Dapagliflozin or a placebo for a three-month post-procedural period. The primary focus was the rate of AFib recurrence, with secondary endpoints measuring left atrial (LA) dilatation and patient functional status.
Key results from the DARE-AF trial
- AFib recurrence: ~30% in both the Dapagliflozin and placebo arms (no significant difference).
- Left atrial dilation: No significant change observed between groups.
- Functional status: No clinical improvement recorded during the 3-month follow-up.
Watch to learn why these results are significant for clinical practice and the current standing of SGLT2i in non-indicated AFib populations.
